Phase I study of imatinib, cisplatin and 5-fluoruracil or capecitabine in advanced esophageal and gastric adenocarcinoma

BACKGROUND: Despite all benefit provided by established therapies prognosis of gastric cancer remains poor. Targeted inhibition of platelet derived growth factor receptor (PDGFR) by imatinib may influence tumor growth and amplify chemotherapeutic effects. METHODS: This phase I study evaluated dose l...

Descripción completa

Detalles Bibliográficos
Autores principales: Mayr, Martina, Becker, Karen, Schulte, Nadine, Belle, Sebastian, Hofheinz, Ralf, Krause, Annekatrin, Schmid, Roland M, Röcken, Christoph, Ebert, Matthias P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3529191/
https://www.ncbi.nlm.nih.gov/pubmed/23228190
http://dx.doi.org/10.1186/1471-2407-12-587

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3529191/
https://www.ncbi.nlm.nih.gov/pubmed/23228190
http://dx.doi.org/10.1186/1471-2407-12-587

Ejemplares similares